Biotech Values

[jq1234]

they delay (like Provenge which showed clear evidence of efficacy).

I am a big suporter of Provenge. However, to say it had clear evidece of efficacy in original BLA is a stretch. Remember, it failed its primary endpoint. The efficacy you stated was from post hoc analysis. FDA should NEVER approve a drug from a study that failed its primary endpoint. They need to run a better trial. They did, and it got approved.